RS58918B1 - Agensi za tretman trostruko negativnog raka dojke - Google Patents

Agensi za tretman trostruko negativnog raka dojke

Info

Publication number
RS58918B1
RS58918B1 RS20190644A RSP20190644A RS58918B1 RS 58918 B1 RS58918 B1 RS 58918B1 RS 20190644 A RS20190644 A RS 20190644A RS P20190644 A RSP20190644 A RS P20190644A RS 58918 B1 RS58918 B1 RS 58918B1
Authority
RS
Serbia
Prior art keywords
agents
breast cancer
negative breast
triple negative
treating triple
Prior art date
Application number
RS20190644A
Other languages
English (en)
Inventor
Gilles Bernard Tremblay
Anna N Moraitis
Mario Filion
Original Assignee
Adc Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adc Therapeutics Sa filed Critical Adc Therapeutics Sa
Publication of RS58918B1 publication Critical patent/RS58918B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RS20190644A 2012-01-09 2013-01-09 Agensi za tretman trostruko negativnog raka dojke RS58918B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584629P 2012-01-09 2012-01-09
PCT/CA2013/000011 WO2013104050A2 (en) 2012-01-09 2013-01-09 Method for treating breast cancer
EP13735811.5A EP2802351B1 (en) 2012-01-09 2013-01-09 Agents for treating triple negative breast cancer

Publications (1)

Publication Number Publication Date
RS58918B1 true RS58918B1 (sr) 2019-08-30

Family

ID=48782004

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190644A RS58918B1 (sr) 2012-01-09 2013-01-09 Agensi za tretman trostruko negativnog raka dojke

Country Status (27)

Country Link
US (2) US20170174753A1 (sr)
EP (2) EP2802351B1 (sr)
JP (3) JP6282597B2 (sr)
KR (1) KR102102239B1 (sr)
CN (2) CN111298119A (sr)
AU (1) AU2013209234B2 (sr)
BR (1) BR112014016723A2 (sr)
CA (2) CA2857400A1 (sr)
CY (1) CY1121667T1 (sr)
DK (1) DK2802351T3 (sr)
EA (2) EA034414B1 (sr)
ES (1) ES2731665T3 (sr)
HK (1) HK1203816A1 (sr)
HR (1) HRP20190946T1 (sr)
HU (1) HUE043888T2 (sr)
IL (2) IL232915A0 (sr)
IN (1) IN2014CN04690A (sr)
LT (1) LT2802351T (sr)
MX (2) MX366973B (sr)
NZ (1) NZ625758A (sr)
PL (1) PL2802351T3 (sr)
PT (1) PT2802351T (sr)
RS (1) RS58918B1 (sr)
SI (1) SI2802351T1 (sr)
TR (1) TR201908872T4 (sr)
WO (1) WO2013104050A2 (sr)
ZA (1) ZA201404798B (sr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336869B (es) 2008-11-03 2016-02-04 Alethia Biotherapeutics Inc Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor.
MX352373B (es) 2011-03-31 2017-11-22 Adc Therapeutics Sa Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno.
CN111298119A (zh) * 2012-01-09 2020-06-19 Adc治疗股份有限公司 用于通过使用肾相关抗原1(kaag1)的抑制剂来治疗三阴性乳癌和基底样乳癌的方法
EP3579883B1 (en) 2017-02-08 2021-08-11 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2024106394A1 (ja) * 2022-11-14 2024-05-23 株式会社Cоgnanо 抗体及び抗体を生産する方法

Family Cites Families (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK365785A (da) 1984-09-17 1986-03-18 Hoffmann La Roche Metalcomplexer
US5075447A (en) 1984-09-17 1991-12-24 Hoffmann-La Roche Inc. Ruthenium complexes useful as carriers for immunologically active materials
GB8601646D0 (en) 1986-01-23 1986-02-26 Davidson R S Binding assay & reagent
US5585279A (en) 1986-01-23 1996-12-17 Davidson; Robert S. Time-resolved luminescence binding assays using a fluorescent transition metal label other than ruthenium
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
CA2071529C (en) 1989-12-28 2001-03-20 Donna Lee Romero Diaromatic substituted anti-aids compounds
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
WO1996013510A1 (en) 1994-10-28 1996-05-09 Procept, Inc. Ruthenium complexes and their use as immunosuppressive agents
US5708022A (en) 1994-10-28 1998-01-13 Procept, Inc. Method for inhibiting immune response
US5712127A (en) 1996-04-29 1998-01-27 Genescape Inc. Subtractive amplification
US5831003A (en) 1996-06-28 1998-11-03 Bayer Corporation Peptides which bind to prothrombin and thrombin
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
EP0991777A1 (en) 1997-06-18 2000-04-12 Ulrich J. Krull Nucleic acid biosensor diagnostics
WO1999031513A1 (en) 1997-12-15 1999-06-24 Lakowicz Joseph R Method and composition for characterizing a sample containing a sample lipid and an assay kit
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
CA2328422A1 (en) 1998-05-13 1999-11-18 Diversys Limited Selection system
JP2002514400A (ja) 1998-05-13 2002-05-21 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 遍在的に発現される新規な遺伝子のリバースストランドによってコードされている腫瘍関連抗原
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US20020106678A1 (en) 1998-06-30 2002-08-08 Robishaw Janet D. cDNA clones encoding human G protein gamma subunits
WO2000001702A1 (en) 1998-07-02 2000-01-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6288221B1 (en) 1998-08-20 2001-09-11 Duke University Methods of synthesis of halogen base-modified oligonucleotides and subsequent labeling with a metal-catalyzed reaction
AU6136599A (en) 1998-09-08 2000-03-27 University Of Maryland At Baltimore Low frequency modulation sensors using nanosecond fluorophores
US6806089B1 (en) 1998-09-08 2004-10-19 University Of Maryland, Baltimore Low frequency modulation sensors using nanosecond fluorophores
US6358953B1 (en) 1998-10-22 2002-03-19 Phillip B. B. Moheno Pterin antineoplastic agents
EP1158984A4 (en) 1998-10-29 2003-05-21 Merck & Co Inc Inhibitors of prenyl protein transferase
CA2367282A1 (en) 1999-03-19 2000-09-28 Simon Fricker Pharmaceutical compositions comprising metal complexes
US6872519B1 (en) 1999-04-27 2005-03-29 Mirus Bio Corporation In vitro process for selecting phage resistant to blood inactivation
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
TR200201413T2 (tr) 1999-09-17 2003-02-21 Millennium Pharmaceuticals, Inc. Faktör Xa' nın inhibitörleri.
WO2001046209A1 (en) 1999-12-20 2001-06-28 Fluorrx, Inc. Fluorescent probes
US20030219806A1 (en) 2000-02-22 2003-11-27 Millennium Pharmaceuticals, Inc. Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
US7585839B2 (en) 2000-02-23 2009-09-08 Zealand Pharma A/S Medical uses of intercellular communication facilitating compounds
US20030215860A1 (en) 2000-02-29 2003-11-20 Millennium Pharmaceuticals, Inc. Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses therefor
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
CA2411971A1 (en) 2000-06-16 2001-12-27 Incyte Genomics, Inc. Proteases
WO2002006339A2 (en) 2000-07-03 2002-01-24 Curagen Corporation Proteins and nucleic acids encoding same
US20050053930A1 (en) 2000-07-18 2005-03-10 David Anderson Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
US7030236B2 (en) 2001-03-09 2006-04-18 Mona Savitri Jhaveri Antisense oligonucleotides tarageting folate receptor alpha, and the use thereof
US20030087250A1 (en) 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20030065157A1 (en) 2001-04-04 2003-04-03 Lasek Amy W. Genes expressed in lung cancer
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
WO2002086443A2 (en) 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
CA2446185C (en) 2001-05-07 2013-06-18 National Research Council Of Canada Enhanced production of recombinant proteins by transient transfection of suspension-growing mammalian cells
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
MXPA03011979A (es) 2001-06-18 2005-04-08 Eos Biotechnology Inc Metodos de diagnostico de cancer de ovario composiciones y metodos para rastrear moduladores de cancer de ovario.
US20040053824A1 (en) 2001-06-29 2004-03-18 Tang Y Tom Extracellular matrix and cell adhesion molecules
US20030099974A1 (en) 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
PT1420809E (pt) 2001-08-31 2012-01-03 Btg Int Ltd Utilização de derivados de ciclopenta[g]quinazolina para tratamento de cancro
CA2458813C (en) 2001-08-31 2011-11-01 Btg International Limited Anti-cancer cyclopenta[g]quinazoline compounds
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
BR0214295A (pt) 2001-11-19 2004-11-09 Elan Pharm Inc Composto, método para tratar um paciente que tem ou prevenir um paciente de adquirir uma doença ou condição, e, método para produzir um composto
AU2002351194A1 (en) 2001-11-30 2003-06-17 Incyte Genomics, Inc. Cell adhesion and extracellular matrix proteins
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
WO2003057725A2 (en) 2002-01-09 2003-07-17 University Of Lausanne Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8048408B2 (en) 2002-01-16 2011-11-01 Biocompatibles Uk Limited Polymer conjugates
CA2474723A1 (en) 2002-01-28 2003-08-07 Keraplast Technologies, Ltd. Bioactive keratin peptides
US6962910B2 (en) 2002-02-01 2005-11-08 Virginia Tech Intellectual Properties, Inc. Supramolecular complexes as photoactivated DNA cleavage agents
WO2003068054A2 (en) 2002-02-13 2003-08-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Identification of ovarian cancer tumor markers and therapeutic targets
DE10206616A1 (de) 2002-02-15 2003-09-04 Qiagen Gmbh Verfahren zur Reduktion der Background-Kontamination nach Markierungsreaktionen
US20040009939A1 (en) 2002-03-05 2004-01-15 Board Of Regent, The University Of Texas System Methods of enhancing immune induction involving MDA-7
CN1305905C (zh) 2002-03-22 2007-03-21 Aprogen株式会社 人源化抗体及其制备方法
WO2003087768A2 (en) 2002-04-12 2003-10-23 Mitokor Targets for therapeutic intervention identified in the mitochondrial proteome
MXPA04011550A (es) 2002-05-20 2005-02-17 Abgenix Inc Tratamiento de carcinoma renal utilizando anticuerpos contra el receptor del factor de crecimiento epidermico.
EP1594447A2 (en) 2002-10-02 2005-11-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1422242A1 (en) 2002-11-22 2004-05-26 Emory University Plastic and elastic protein copolymers
CN1768139A (zh) 2003-02-10 2006-05-03 独立行政法人产业技术总合研究所 通过dna干扰调控基因的表达
WO2004087874A2 (en) 2003-03-28 2004-10-14 Nuvelo, Inc. Novel nucleic acids and polypeptides
EP1635866A2 (en) 2003-05-20 2006-03-22 Cellpep S.A. Modified antiviral peptides with increased activity and cell membrane affinity
EP1636363A1 (en) 2003-05-21 2006-03-22 GeneSense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
US20050008649A1 (en) 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
US20060078941A1 (en) 2003-06-09 2006-04-13 Santin Alessandro D Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
WO2005004795A2 (en) 2003-06-09 2005-01-20 University Of Cincinnati Compositions and methods for targeted drug delivery
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
GB0318096D0 (en) 2003-08-01 2003-09-03 Queen Mary & Westfield College Vaccine
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
US20070178458A1 (en) 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
US20050147621A1 (en) 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7202234B2 (en) 2003-10-24 2007-04-10 Eisai Co., Ltd. Compounds and methods for treating Toll-like receptor 2-related diseases and conditions
US20050153333A1 (en) 2003-12-02 2005-07-14 Sooknanan Roy R. Selective terminal tagging of nucleic acids
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
US20090169520A1 (en) 2004-01-09 2009-07-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, Pharmaceutical Compositions and Therapeutic Methods of Preventing and Treating Diseases and Disorders Associated With Amyloid Fibril Formation
WO2005070456A2 (en) 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
AU2005213464A1 (en) 2004-02-06 2005-08-25 Wyeth Diagnosis and therapeutics for cancer
EP1723428A2 (en) 2004-02-19 2006-11-22 Yale University Corporation Identification of cancer protein biomarkers using proteomic techniques
EA200601575A1 (ru) 2004-03-01 2007-06-29 Пептера Фармасьютикалс Лтд. Казеиновые пептиды и их терапевтическое применение
EP1784430A1 (en) 2004-07-06 2007-05-16 Warwick Effect Polymers Limited Living radical polymerization initiator comprising a functional group capable of reacting with polyeptides or the like, comb polymer obtained therewith , polypeptide conjugates and drugs obtained therefrom.
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7553944B2 (en) 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
US20080280317A1 (en) 2004-08-27 2008-11-13 Northeastern University Comprehensive Characterization Of Complex Proteins At Trace Levels
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
WO2006027202A1 (en) 2004-09-06 2006-03-16 Unite De Recherche En Biotherapie Et Oncologie (Rubio) Generation of multiparent cell hybrids
US7829708B2 (en) 2004-09-08 2010-11-09 Chelsea Therapeutics, Inc. Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation
US8247371B2 (en) 2004-10-14 2012-08-21 Yale University Therapy with Clostridium perfringens enterotoxin to treat ovarian and uterine cancer
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US7429567B2 (en) 2005-01-04 2008-09-30 The Brigham And Women's Hospital, Inc. Sustained delivery of PDGF using self-assembling peptide nanofibers
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
WO2006080323A1 (ja) 2005-01-27 2006-08-03 Asahi Kasei Pharma Corporation ヘテロ6員環化合物及びその用途
NZ597997A (en) 2005-02-14 2013-10-25 Epitopix Llc Antibody compositions that bind polypeptides from staphylococcus aureus
RU2007135030A (ru) 2005-02-24 2009-03-27 Симайнз, Инк. (Us) Композиции и способы классификации биологических образцов
US8551774B2 (en) 2005-03-17 2013-10-08 National Research Council Of Canada Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the Gly-Gly-Ala domain for enhanced transient gene expression
AU2006227379B2 (en) 2005-03-17 2011-10-20 President And Fellows Of Harvard College Synthesis of avrainvillamide, stephacidin B, and analogues thereof
FR2885525B1 (fr) 2005-05-13 2009-09-18 Urodelia Sa Medicament notamment anti-cancereux, destine a des traitements par immunotherapie, en particulier autologue
CA2612102C (en) 2005-06-13 2016-02-09 Cleveland Biolabs, Inc. Methods of protecting against apoptosis using lipopeptides
CN101346468B (zh) 2005-06-15 2016-03-30 麻省理工学院 含胺脂质和其用途
JP5237799B2 (ja) 2005-06-27 2013-07-17 エグゼリクシス パテント カンパニー エルエルシー ピラゾールベースのlxrモジュレーター
WO2007005249A2 (en) 2005-06-29 2007-01-11 Hyperbranch Medical Technology, Inc. Nanoparticles and dendritic-polymer-based hydrogels comprising them
US7494788B2 (en) 2005-07-11 2009-02-24 Molecular Kinetics, Inc. Entropic bristle domain sequences and their use in recombinant protein production
US7820790B2 (en) 2005-07-13 2010-10-26 Amgen Mountain View Inc. IL-6 binding proteins
US20090005268A1 (en) 2005-07-18 2009-01-01 Epigenomics Ag Compositions and Methods for Cancer Diagnostics Comprising Pan-Cancer Markers
GB0516058D0 (en) 2005-08-04 2005-09-14 Oxford Genome Sciences Uk Ltd New protein isoforms and uses thereof
GB0517293D0 (en) 2005-08-24 2005-10-05 Cancer Rec Tech Ltd Vectors and uses thereof
US8703903B2 (en) 2005-09-15 2014-04-22 Alk-Abello A/S Method for quantification of allergens
WO2007073432A2 (en) 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
WO2007045876A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co. Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
US7557213B2 (en) 2005-11-10 2009-07-07 Chemocentryx, Inc. Substituted quinolones and methods of use
EP1954134B1 (en) 2005-11-23 2011-09-14 Merck Sharp & Dohme Corp. Process for synthesizing a 2-phenyl-1h-phenantrho[9,10-d]imidazole derivative
KR101049859B1 (ko) 2007-11-28 2011-07-19 대한민국 N-말단 pI 값 조절에 의한 수용성 재조합 단백질 생산방법
MX2008011280A (es) 2006-03-06 2008-09-12 Symphogen As Anticuerpor policlonal recombinante para el tratamiento de infecciones por el virus sincitial respiratorio.
JP5167155B2 (ja) 2006-03-09 2013-03-21 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法
WO2007104948A2 (en) 2006-03-10 2007-09-20 Warwick Effect Polymers Ltd. Polymers
WO2007110755A1 (en) 2006-03-27 2007-10-04 Medical Therapies Limited Prophylaxis or treatment of cardiovascular inflammation
ATE548380T1 (de) 2006-04-20 2012-03-15 Kringle Pharma Inc Mutante des hgf-precursor-proteins und aktivierte form davon
WO2007131191A2 (en) 2006-05-05 2007-11-15 Perkinelmer Life And Analytical Sciences Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases
EP2348106B1 (en) 2006-05-08 2014-07-02 Adaerata, Limited Partnership Chimeric proteins, cells comprising same, and assays using same
US20120128661A1 (en) 2006-06-23 2012-05-24 Alethia Biotherapeutics Inc. Polynucleotide and polypeptide sequences involved in cancer
EP2032701B1 (en) 2006-06-23 2013-11-27 Alethia Biotherapeutics Inc. Polynucleotides and polypeptides involved in cancer
EP2041556A1 (en) 2006-06-28 2009-04-01 RGB Technologies AB A sensor kit and a system for detecting an analyte in a test environment
US8198046B2 (en) 2006-07-11 2012-06-12 Danisco Us Inc. KEX2 cleavage regions of recombinant fusion proteins
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2121747A2 (en) 2006-07-27 2009-11-25 Oxford Genome Sciences (UK) Limited New protein isoforms and uses thereof
WO2008016356A2 (en) 2006-08-02 2008-02-07 Genizon Biosciences Genemap of the human genes associated with psoriasis
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP2066806A2 (fr) 2006-09-07 2009-06-10 Laurence Faure Test pharmaco diagnostique ciblant l'oncologie
WO2008033932A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors
US7662820B2 (en) 2006-10-30 2010-02-16 Sanrx Pharmaceuticals, Inc. Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
EP2114948B1 (en) 2006-12-28 2014-06-25 AbbVie Inc. Inhibitors of poly(adp-ribose)polymerase
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
SG177959A1 (en) 2007-01-09 2012-02-28 Cleveland Biolabs Inc Methods for increasing and mobilizing hematopoietic stem cells
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
US20080311145A1 (en) 2007-04-04 2008-12-18 Specigen, Inc. Protein cage immunotherapeutics
WO2009009186A2 (en) 2007-04-13 2009-01-15 The Regents Of The University Of California Receptors useful for gas phase chemical sensing
US20080306007A1 (en) 2007-04-30 2008-12-11 Newcastle Innovation Limited Agents for prophylaxis or treatment of neurological related diseases and conditions
JP2010526091A (ja) 2007-04-30 2010-07-29 インテザイン テクノロジーズ, インコーポレイテッド 癌の処置のための生物学的な標的基の改変
US8143372B2 (en) 2007-05-21 2012-03-27 Children's Hospital & Research Center Oakland Synthetic regulators of ferritin protein nanocage pores and methods of use thereof
US20090176664A1 (en) 2007-06-01 2009-07-09 Keting Chu High density peptide arrays containing kinase or phosphatase substrates
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
US9018138B2 (en) 2007-08-16 2015-04-28 The Johns Hopkins University Compositions and methods for generating and screening adenoviral libraries
BRPI0817079A2 (pt) 2007-09-07 2016-10-11 Symphogen As processos para fabricação recombinante de anticorpos anti-rsv
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP6039879B2 (ja) 2007-11-05 2016-12-07 ノルディック・ビオサイエンス・エー/エスNordic Bioscience A/S Cvdリスク評価のための生化学マーカー
US20100298368A1 (en) 2007-11-06 2010-11-25 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
EP2071334A1 (en) 2007-12-14 2009-06-17 Transmedi SA Compositions and methods of detecting TIABS
US20110165223A1 (en) 2008-01-02 2011-07-07 The Johns Hopkins University Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen
JP2011515666A (ja) 2008-03-14 2011-05-19 ドナー, インコーポレイテッド トリプルネガティブ乳がんに関連するdna修復タンパク質およびその使用法
WO2009114942A1 (en) 2008-03-20 2009-09-24 University Health Network Thymidylate kinase fusions and uses thereof
WO2009134370A2 (en) 2008-04-30 2009-11-05 University Of Vermont And State Agricultural College Methods and products relating to gsk3 beta regulation
US8246991B2 (en) 2008-05-09 2012-08-21 Surmodics Pharmaceuticals, Inc. Biocompatible and biodegradable elastomeric polymers
US20110123637A1 (en) 2008-05-26 2011-05-26 Universitat Zurich Protamine/rna nanoparticles for immunostimulation
EP2307362A4 (en) 2008-07-03 2012-05-09 Panmira Pharmaceuticals Llc ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
CA2730428A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
PL2328893T3 (pl) 2008-08-08 2013-09-30 Synta Pharmaceuticals Corp Związki triazolowe modulujące aktywność Hsp90
WO2010033207A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides
WO2010033220A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
MX336869B (es) 2008-11-03 2016-02-04 Alethia Biotherapeutics Inc Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor.
CA2766747C (en) 2009-07-10 2019-04-02 Innate Pharma Tlr3 binding agents
WO2011017687A1 (en) * 2009-08-06 2011-02-10 Ray Partha S Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
WO2011054112A1 (en) * 2009-11-03 2011-05-12 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of kidney associated antigen 1
SG183532A1 (en) * 2010-03-11 2012-09-27 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
US20110233107A1 (en) 2010-03-23 2011-09-29 Emily Jainine Lockett Personal Cosmetic Palette
MX352373B (es) 2011-03-31 2017-11-22 Adc Therapeutics Sa Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno.
CN111298119A (zh) * 2012-01-09 2020-06-19 Adc治疗股份有限公司 用于通过使用肾相关抗原1(kaag1)的抑制剂来治疗三阴性乳癌和基底样乳癌的方法
JP6554959B2 (ja) 2015-07-14 2019-08-07 富士通株式会社 情報処理装置、コンパイル方法、およびコンパイルプログラム

Also Published As

Publication number Publication date
EP2802351B1 (en) 2019-03-27
JP2018024701A (ja) 2018-02-15
US20170174753A1 (en) 2017-06-22
JP2018203755A (ja) 2018-12-27
US20190119366A1 (en) 2019-04-25
CY1121667T1 (el) 2020-07-31
EP2802351A4 (en) 2016-04-13
PT2802351T (pt) 2019-06-27
TR201908872T4 (tr) 2019-07-22
PL2802351T3 (pl) 2019-11-29
JP6392435B2 (ja) 2018-09-19
DK2802351T3 (da) 2019-05-13
CN111298119A (zh) 2020-06-19
IL254964B (en) 2019-03-31
CA3115623A1 (en) 2013-07-18
WO2013104050A2 (en) 2013-07-18
EA201491352A1 (ru) 2015-01-30
HRP20190946T1 (hr) 2019-07-26
IL232915A0 (en) 2014-07-31
AU2013209234A1 (en) 2014-06-26
EP3533468A1 (en) 2019-09-04
MX2019009121A (es) 2019-09-16
CA2857400A1 (en) 2013-07-18
WO2013104050A3 (en) 2015-04-02
EA034414B1 (ru) 2020-02-05
EP2802351A2 (en) 2014-11-19
ES2731665T3 (es) 2019-11-18
HUE043888T2 (hu) 2019-09-30
IN2014CN04690A (sr) 2015-09-18
AU2013209234B2 (en) 2017-11-09
EA201992513A1 (ru) 2020-05-31
HK1203816A1 (en) 2015-11-06
JP6282597B2 (ja) 2018-02-21
MX2014008410A (es) 2014-12-08
BR112014016723A2 (pt) 2018-07-24
CN104955477A (zh) 2015-09-30
MX366973B (es) 2019-08-01
CN104955477B (zh) 2020-03-03
LT2802351T (lt) 2019-06-25
SI2802351T1 (sl) 2019-07-31
US11084872B2 (en) 2021-08-10
ZA201404798B (en) 2020-07-29
JP2015511216A (ja) 2015-04-16
IL254964A0 (en) 2017-12-31
NZ625758A (en) 2016-05-27
KR20140116093A (ko) 2014-10-01
KR102102239B1 (ko) 2020-04-21

Similar Documents

Publication Publication Date Title
IL289300A (en) Combined treatment for cancer
IL267242B (en) Cancer treatment
IL237558A0 (en) Methods for treating locally advanced breast cancer
HK1254859A1 (zh) 治療乳腺癌的方法
IL254964A0 (en) A method for treating breast cancer
HK1210023A1 (en) Cancer treatment
HK1210136A1 (en) Ingenol-derived compounds that can be used for treating cancer
EP2886122A4 (en) AGENT FOR THE TREATMENT OF CANCER
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
EP2888594A4 (en) METHOD OF DETERMINING TREATMENT FOR USE AGAINST BREAST CANCER
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
GB201222563D0 (en) Cancer treatment
IL239231A0 (en) Combined cancer treatment